EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
VYNE Therapeutics Inc. (VYNE) had EBIT Margin of -5250.51% for the most recently reported fiscal quarter, ending 2024-06-30.
| Income Statement Financials | |
$0.20M |
|
$-9.41M |
|
-- |
|
$0.20M |
|
$10.59M |
|
$-10.40M |
|
$1.00M |
|
$-9.39M |
|
$-9.39M |
|
$-9.39M |
|
$-9.39M |
|
$-9.41M |
|
$-9.39M |
|
$-10.40M |
|
$-11.01M |
|
42.59M |
|
42.59M |
|
$-0.22 |
|
$-0.22 |
|
| Balance Sheet Financials | |
$83.78M |
|
-- |
|
$2.87M |
|
$86.65M |
|
$11.75M |
|
-- |
|
$0.03M |
|
$11.78M |
|
$74.87M |
|
$74.87M |
|
$74.87M |
|
14.54M |
|
| Cash Flow Statement Financials | |
$-16.46M |
|
$15.45M |
|
$-0.01M |
|
$30.67M |
|
$29.66M |
|
$-1.02M |
|
$1.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.13 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-5250.51% |
|
|
EBIT Margin |
-5250.51% |
-- |
|
-4744.95% |
|
-4750.51% |
|
$-16.46M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-12.55% |
|
-12.55% |
|
-10.84% |
|
-12.55% |
|
$5.15 |
|
$-0.39 |
|
$-0.39 |
|